Mar 16, 2022 / 03:20PM GMT
Jay Olson - Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst
Hello, everyone, and welcome to Oppenheimer's 32nd Annual Healthcare conference. I am Jay Olson, one of the biotech analyst at Oppenheimer and I want to thank you all for joining us here today. It's a real pleasure to welcome Amgen to our conference, and it's an honor to introduce Arvind Sood, Head of Investor Relations, Peter Griffith, Chief Financial Officer; and Rob Lenz, Head of Global Development. We're super excited about all the progress at Amgen and really appreciate the opportunity to catch up with you all today. So thank you so much for participating in our conference. And with that, I'll turn it over to you, Peter, for opening remarks.
Peter H. Griffith - Amgen Inc. - Executive VP & CFO
Well, Jay, thank you very much, and we really genuinely appreciate the invitation to the 32nd Oppenheimer Healthcare Conference. So we recently had an opportunity to discuss what we expect to deliver through 2030 with the investment community. February 8 was our
Amgen Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers